Y-mAbs Therapeutics, Inc. (YMAB) Social Stream



Y-mAbs Therapeutics, Inc. (YMAB): $10.33

-0.28 (-2.64%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Y-mAbs Therapeutics Inc (YMAB) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Y-mAbs Therapeutics Inc.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-09 6 $68 $39 $54.4 $11.8 361.02%
2021-11-16 6 $68 $30 $49 $11.8 315.25%
2021-12-22 6 $68 $25 $46.2 $11.8 291.53%
2022-01-03 6 $68 $25 $45.6 $11.8 286.44%
2022-01-06 6 $68 $25 $43.4 $11.8 267.8%
2022-02-17 6 $68 $15 $41.4 $11.8 250.85%
2022-02-25 6 $68 $15 $40 $11.8 238.98%
2022-02-28 6 $63 $15 $35.8 $11.8 203.39%
2022-03-08 6 $63 $15 $33.8 $11.8 186.44%

The Trend in the Analyst Price Target


YMAB's average price target has moved down $11.76 over the prior 21 months.

YMAB reports an average of 150.71% for its upside potential over the past 48 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-03 6 70 45 59.63 30.28 96.93%
2021-05-08 10 70 45 57.88 34.20 69.24%
2021-07-24 10 68 45 57.00 35.33 61.34%
2021-09-19 8 68 41 55.00 32.30 70.28%
2021-12-15 6 68 25 46.20 16.60 178.31%

YMAB Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.67 4 0 2 0 0 6

The Trend in the Broker Recommendations


Over the past 39 weeks, YMAB's average broker recommendation rating worsened by 0.07.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • In terms of how Y-mAbs Therapeutics Inc fares relative to all US stocks, note that its variance in analysts' estimates is lower than -813.92% of that group.
  • To contextualize these metrics, consider that out of all US stocks, Y-mAbs Therapeutics Inc's upside potential (average analyst target price relative to current price) is greater than 905.12% of them.
  • YMAB has a higher average analyst price target than 630.08% of Pharmaceutical Products stocks.
  • In the context of stocks in the mid market cap category, Y-mAbs Therapeutics Inc's number of analysts covering the stock is higher than 374.2% of them.

Stocks similar to Y-mAbs Therapeutics Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are XNCR, VERV, and VALN.

What is the outlook for YMAB? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6047 seconds.